Patents Assigned to Alkermes
  • Publication number: 20130004573
    Abstract: The invention relates to a controlled release composition comprising a combination of isosorbide dinitrate and hydralazine, such as hydralazine hydrochloride, that in operation delivers the drug in a pulsed or multi-modal manner for the treatment of angina, ischaemic heart disease, arterial hypertension and related disease conditions. Preferably, the isosorbide dinitrate and hydralazine hydrochloride can be released from the dosage form in an erodable, diffusion and/or osmotic-controlled release profile.
    Type: Application
    Filed: September 7, 2012
    Publication date: January 3, 2013
    Applicant: Alkermes Pharma Ireland Limited
    Inventors: Gurvinder Singh Rekhi, Richard Sidwell, Sharon Hamm
  • Patent number: 8338428
    Abstract: The present invention relates, in part, to the discovery that a pharmaceutical composition comprising aripiprazole and a carrier administered in a bolus injection resulted in an extended release profile similar to that obtained by the injection of a poly lactide-co-glycolide microsphere formulation containing the active agent. This surprising result suggests that pharmacologically beneficial extended release formulations without the complexities and expense associated with the manufacture microspheres.
    Type: Grant
    Filed: March 15, 2012
    Date of Patent: December 25, 2012
    Assignee: Alkermes, Inc.
    Inventor: Josiah Brown
  • Patent number: 8338427
    Abstract: The present invention relates, in part, to the discovery that a pharmaceutical composition comprising aripiprazole and a carrier administered in a bolus injection resulted in an extended release profile similar to that obtained by the injection of a poly lactide-co-glycolide microsphere formulation containing the active agent. This surprising result suggests that pharmacologically beneficial extended release formulations without the complexities and expense associated with the manufacture microspheres.
    Type: Grant
    Filed: October 15, 2008
    Date of Patent: December 25, 2012
    Assignee: Alkermes, Inc.
    Inventor: Josiah Brown
  • Publication number: 20120315336
    Abstract: Described are injectable formulations of particulate olanzapine that produce a prolonged duration of action upon administration, and methods of making and using such formulations. The injectable formulations comprise particulate olanzapine.
    Type: Application
    Filed: May 3, 2012
    Publication date: December 13, 2012
    Applicant: Alkermes Pharma Ireland Limited
    Inventors: Stephen B. Ruddy, David Czekai, Gary Liversidge, Scott A. Jenkins, Elaine M. Liversidge
  • Patent number: 8323641
    Abstract: The present invention is directed to nanoparticulate active agent compositions comprising lysozyme as a surface stabilizer. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate active agent composition of the invention.
    Type: Grant
    Filed: November 12, 2008
    Date of Patent: December 4, 2012
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Christian F. Wertz, Niels P. Ryde
  • Patent number: 8309133
    Abstract: The present invention is directed to nanoparticulate quinazoline derivative compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The nanoparticulate quinazoline derivative particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of hyperproliferative disorders, such as cancer and other neoplastic diseases. The compositions may include quinazolinamine derivatives such as erlotinib or a salt thereof.
    Type: Grant
    Filed: April 12, 2006
    Date of Patent: November 13, 2012
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Gary G. Liversidge, Scott Jenkins
  • Patent number: 8309136
    Abstract: Disclosed are in vitro methods for evaluating the in vivo redispersibility of dosage forms of poorly water-soluble active agents. The methods utilize media representative of in vivo human physiological conditions.
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: November 13, 2012
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Eugene R. Cooper, John A. Bullock, John R. Chippari, John L. Schaefer, Rakesh A. Patel, Rajeev Jain, Joost Strasters, Niels P. Ryde, Stephen B. Ruddy
  • Patent number: 8293277
    Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.
    Type: Grant
    Filed: June 22, 1999
    Date of Patent: October 23, 2012
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Jon Swanson, Rajeev A. Jain, Robert Hontz, John G. Devane, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd, Gary Liversidge
  • Publication number: 20120258981
    Abstract: The invention relates to a process for the synthesis of quaternized compounds of formula:
    Type: Application
    Filed: April 5, 2012
    Publication date: October 11, 2012
    Applicant: Alkermes, Inc.
    Inventor: Scott Duncan
  • Publication number: 20120258914
    Abstract: Methods of forming compositions for the sustained release of water soluble active agents, including biologically active polypeptides and products produced by the process are described. Improved product characteristics and ease of scale-up can be achieved using a novel coacervation process wherein at least one coacervation agent is added to the mixture comprising the active agent and the polymer in at least two distinct stages.
    Type: Application
    Filed: December 22, 2011
    Publication date: October 11, 2012
    Applicant: Alkermes, Inc.
    Inventors: Rajesh Kumar, Gregory Troiano, J. Michael Ramstack, Paul Herbert, Michael Figa
  • Patent number: 8236352
    Abstract: The present invention is directed to nanoparticulate compositions comprising glipizide. The glipizide particles of the composition preferably have an effective average particle size of less than about 2 microns.
    Type: Grant
    Filed: November 5, 2003
    Date of Patent: August 7, 2012
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: H. William Bosch, Niels P. Ryde, Rajeev A. Jain, Jon Swanson, Robert Hontz, John G. Devane, Kenneth Ian Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd, Gary G. Liversidge
  • Patent number: 8187672
    Abstract: Methods for preparing microparticles having reduced residual solvent levels. Microparticles are contacted with a non-aqueous washing system to reduce the level of residual solvent in the microparticles. Preferred non-aqueous washing systems include 100% ethanol and a blend of ethanol and heptane. A solvent blend of a hardening solvent and a washing solvent can be used to harden and wash microparticles in a single step, thereby eliminating the need for a post-hardening wash step.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: May 29, 2012
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Michael E. Rickey, J. Michael Ramstack, Rajesh Kumar
  • Patent number: 8158153
    Abstract: Nanoparticulate bisphosphonate compositions, having an effective average particle size of less than 2000 nm, are described. The compositions are useful in treating bone resorption in a mammal.
    Type: Grant
    Filed: March 17, 2006
    Date of Patent: April 17, 2012
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Gary G. Liversidge, Scott Jenkins
  • Publication number: 20120077800
    Abstract: The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
    Type: Application
    Filed: August 23, 2011
    Publication date: March 29, 2012
    Applicant: Alkermes, Inc.
    Inventors: Daniel Deaver, Mark Todtenkopf
  • Patent number: 8129339
    Abstract: The invention relates to compositions and methods for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein a biologically active polypeptide, and a corticosteroid to modify the release profile and provide increased bioavailability.
    Type: Grant
    Filed: November 6, 2008
    Date of Patent: March 6, 2012
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Henry R. Costantino, Joyce M. Hotz, James R. Dasch, M. Gary I. Riley, Paul A. Burke, Susan A. Steitz-Abadi, Stephen E. Zale
  • Patent number: 8124057
    Abstract: There invention discloses aqueous dispersions of nanoparticulate aerosol formulations, dry powder nanoparticulate aerosol formulation, propellant-based aerosol formulations, methods of using the formulations in aerosol delivery devices, and methods of making such formulations. The nanoparticles of the aqueous dispersions or dry powder formulations comprise insoluble drug particles having a surface modifier on the surface thereof.
    Type: Grant
    Filed: January 26, 2009
    Date of Patent: February 28, 2012
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: H. William Bosch, Kevin D. Ostrander, Eugene R. Cooper
  • Patent number: 8119163
    Abstract: The present invention provides a composition comprising a cefditoren, or a salt, derivative, prodrug, or other form thereof, for example, cefditoren pivoxil, useful in the treatment and prevention of infections and related conditions. The invention provides a composition which comprises nanoparticulate particles comprising the cefditoren, or a salt, derivative, prodrug, or other form thereof and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. The invention provides also a composition that delivers a cefditoren, or a salt, derivative, prodrug, or other form thereof, or nanoparticles comprising the same, in a pulsatile or continuous manner.
    Type: Grant
    Filed: February 5, 2007
    Date of Patent: February 21, 2012
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: John G Devane, Paul Stark, Niall M. N. Fanning, Gurvinder Singh Rekhi, Scott A. Jenkins, Gary Liversidge
  • Publication number: 20120015866
    Abstract: The present invention relates to prodrugs of parent drug compounds containing heteroaromatic NH groups.
    Type: Application
    Filed: December 23, 2010
    Publication date: January 19, 2012
    Applicant: Alkermes, Inc.
    Inventors: Laura Cook Blumberg, Örn Almarsson
  • Patent number: 8097282
    Abstract: There is disclosed an aerosol comprising droplets of an aqueous dispersion of nanoparticles, said nanoparticles comprising insoluble therapeutic or diagnostic agent particles having a surface modifier on the surface thereof. There is also disclosed a method for making the aerosol and methods for treatment and diagnosis using the aerosol.
    Type: Grant
    Filed: April 18, 2008
    Date of Patent: January 17, 2012
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Ray W. Wood, Lan DeCastro, H. William Bosch
  • Publication number: 20120010412
    Abstract: The present invention relates to a process for the synthesis of a compound of formula I:
    Type: Application
    Filed: April 28, 2011
    Publication date: January 12, 2012
    Applicant: Alkermes, Inc.
    Inventor: Scott Duncan